1. Scrip
  2. >>Business

Jemperli Results In Endometrial Cancer Help GSK Build ‘Backbone’ In Immunotherapy

Strong Results But Merck & Co’s Keytruda Also Competing

 
• By Andrew McConaghie

Latecomer PD-1/L1 drug Jemperli has achieved impressive Phase III results in first line endometrial cancer, and GSK hopes it can “redefine” care, especially in dMMR patients. Rival Merck, however, has other ideas.

new gsk logo and hq
GSK needs its own PD1/L1 therapy 'backbone' on which to build future cancer therapy combinations. • Source: GSK

GSK has scored a hit with early results from a pivotal study of its PD-L1 inhibitor cancer therapy Jemperli, showing the drug significantly extended progression-free survival, the primary endpoint, when added to standard-of-care chemotherapy in patients with with primary advanced or recurrent endometrial cancer.

The company believes the interim results from the Phase III RUBY study show that Jemperli (dostarlimab) can “redefine” treatment of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Amgen’s ‘Stunning’ VESALIUS Results Could Push Repatha Into The Mainstream

 
• By Mandy Jackson

Cardiologists know PCSK9 inhibition is a powerful LDL-lowering tool and now Amgen’s VESALIUS data show it may be worth adding to the primary care physician’s toolbox for prevention of high-risk patients’ first major cardiovascular events.

J&J Plans Educational Push After Darzalex Smoldering Myeloma Approval

 
• By Alaric DeArment

The FDA approved the anti-CD38 monoclonal antibody, a mainstay of multiple myeloma for a decade, for high-risk smoldering disease.

Lilly/Novo Get Priority Reviews For Lowering Drug Prices

 
• By Jessica Merrill

Novo Nordisk’s high-dose semaglutide for obesity and Lilly’s oral obesity candidate orforglipron were given priority review vouchers by the US Food and Drug Administration.

Bavarian Nordic Future Looks Bright Despite Failed Takeover Bid

 
• By Kevin Grogan

Even with Innosera's sweetened offers and a boardroom recommendation, the proposed acquisition could not clear the minimum 66.67% shareholder approval level.

More from Scrip

Lilly’s Eloralintide Success Sets Bar For Amylin Rivals

 
• By Andrew McConaghie

The US pharma giant may have a best-in-class amylin agonist to go with incretin blockbuster Zepbound, but challengers could still go one better on safety and tolerability.

Bavarian Nordic Future Looks Bright Despite Failed Takeover Bid

 
• By Kevin Grogan

Even with Innosera's sweetened offers and a boardroom recommendation, the proposed acquisition could not clear the minimum 66.67% shareholder approval level.

Centessa’s Sleep Disorder Drug Shows Broad Potential But Faces Tough Competition

 
• By Sushmita Panda

Pivotal data next year will be key for the early-stage biotech as analysts remain divided on ORX750's potential.